Latest filing published 18 Dec 2024 for Arrowhead Pharmaceuticals, INC., €104k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Douglas B. Given (board member) discloses dealings in Arrowhead Pharmaceuticals, Inc. to SEC (Form 4). We count 12 filings; the first trade dates from 1 January 2016 and the latest from 16 December 2024.
The open-market record consists of 7 sales worth €1.1M, with no purchase. Besides market trades, the filings include 4 share grants. 2024 to date brings no purchases and 3 sales.
Most recently, on 18 December 2024, the filings show an open-market sale worth €104k in Arrowhead Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations